GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Insider Ownership
中文

Alimera Sciences (Alimera Sciences) Insider Ownership : 3.16 % (As of Apr. 24, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alimera Sciences's insider ownership is 3.16%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alimera Sciences's Institutional Ownership is 3.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alimera Sciences's Float Percentage Of Total Shares Outstanding is 93.43%.


Alimera Sciences Insider Ownership Historical Data

The historical data trend for Alimera Sciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Insider Ownership Chart

Alimera Sciences Historical Data

The historical data trend for Alimera Sciences can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Insider Ownership 11.69 11.69 1.96 1.96 3.16 3.16 3.16 3.15 3.15 3.16

Alimera Sciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Alimera Sciences (Alimera Sciences) Business Description

Traded in Other Exchanges
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076